Literature DB >> 11719221

The KEN box regulates Clb2 proteolysis in G1 and at the metaphase-to-anaphase transition.

C Hendrickson1, M A Meyn, L Morabito, S L Holloway.   

Abstract

Clb2 mitotic cyclin inhibits cell cycle progression by preventing mitotic exit and DNA synthesis. To allow cell cycle progression, Clb2 proteolysis is triggered by Cdc20 during the metaphase-to-anaphase (M-A) transition and by Hct1 during mitotic exit and G1 [1-6]. A cis element called the destruction box is required for this proteolysis [7-11]. Recently, an additional cis element called the "KEN box" was also shown to be required for proteolysis of human CDC20 and Securin [3,12]. Using a novel color assay, we show that a Clb2 KEN box is required to target a fusion protein containing the first 124 amino acids of Clb2 for proteolysis. We further show that full-length Clb2 bearing mutations in the KEN box is degraded efficiently during the M-A transition, but poorly during G1. If the destruction box of Clb2 is mutated in combination with mutation of the KEN box, then this form of Clb2 is more stable than Clb2 bearing either mutation by itself during both M-A and G1. Our results show that the KEN box and the destruction box act together during both M-A and G1 to regulate Clb2 proteolysis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719221     DOI: 10.1016/s0960-9822(01)00564-4

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  14 in total

1.  Timing of APC/C substrate degradation is determined by fzy/fzr specificity of destruction boxes.

Authors:  Amit Zur; Michael Brandeis
Journal:  EMBO J       Date:  2002-09-02       Impact factor: 11.598

2.  Quantitative characterization of a mitotic cyclin threshold regulating exit from mitosis.

Authors:  Frederick R Cross; Lea Schroeder; Martin Kruse; Katherine C Chen
Journal:  Mol Biol Cell       Date:  2005-02-16       Impact factor: 4.138

3.  Substrate Recognition by the Cdh1 Destruction Box Receptor Is a General Requirement for APC/CCdh1-mediated Proteolysis.

Authors:  Liang Qin; Dimitrius Santiago P S F Guimarães; Michael Melesse; Mark C Hall
Journal:  J Biol Chem       Date:  2016-05-23       Impact factor: 5.157

4.  Mismatch repair, but not heteroduplex rejection, is temporally coupled to DNA replication.

Authors:  Hans Hombauer; Anjana Srivatsan; Christopher D Putnam; Richard D Kolodner
Journal:  Science       Date:  2011-12-23       Impact factor: 47.728

5.  Proteome-wide discovery of evolutionary conserved sequences in disordered regions.

Authors:  Alex N Nguyen Ba; Brian J Yeh; Dewald van Dyk; Alan R Davidson; Brenda J Andrews; Eric L Weiss; Alan M Moses
Journal:  Sci Signal       Date:  2012-03-13       Impact factor: 8.192

6.  Loss of Cdc20 causes a securin-dependent metaphase arrest in two-cell mouse embryos.

Authors:  Min Li; J Philippe York; Pumin Zhang
Journal:  Mol Cell Biol       Date:  2007-02-26       Impact factor: 4.272

7.  A novel RING finger protein, human enhancer of invasion 10, alters mitotic progression through regulation of cyclin B levels.

Authors:  Garabet G Toby; Wahiba Gherraby; Thomas R Coleman; Erica A Golemis
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

8.  Unique D box and KEN box sequences limit ubiquitination of Acm1 and promote pseudosubstrate inhibition of the anaphase-promoting complex.

Authors:  Eunyoung Choi; J Michael Dial; Dah-Eun Jeong; Mark C Hall
Journal:  J Biol Chem       Date:  2008-07-02       Impact factor: 5.157

9.  Cdc14 inhibits transcription by RNA polymerase I during anaphase.

Authors:  Andrés Clemente-Blanco; María Mayán-Santos; David A Schneider; Félix Machín; Adam Jarmuz; Herbert Tschochner; Luis Aragón
Journal:  Nature       Date:  2009-01-21       Impact factor: 49.962

10.  Loss of spindle assembly checkpoint-mediated inhibition of Cdc20 promotes tumorigenesis in mice.

Authors:  Min Li; Xiao Fang; Zhubo Wei; J Philippe York; Pumin Zhang
Journal:  J Cell Biol       Date:  2009-06-15       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.